Clinical Information

This test is appropriate for patients previously diagnosed wth B-ALL and  may be run at any time point in therapy.

This is a COG approved MRD test for patients enrolled on AALL0932 and AALL1131. Day 29 of COG protocol. May be ordered post consolidation; other timepoints in therapy also accepted.

Minimal residual disease (MRD) is a powerful prognostic factor for predicting outcome in pediatric B cell acute lymphoblastic leukemia (B-ALL).  This flow cytometry assay is an effective method for measuring MRD and is the COG approved MRD test for patients enrolled on AALL0932 and AALL1131 Day 8 of COG protocol; other time points in therapy also accepted.  This flow cytometry assay involves the staining of white blood cells in a bone marrow sample with a viability dye and monoclonal antibody to CD3, CD9, CD10, CD13, CD19, CD20, CD33, CD34, CD38, CD45, CD58, and CD71. Additional markers may be evaluated if phenotypic charateristics indicate the need. This flow cytometric assay has the ability to enumerate and characterize very small populations of abnormal cells, often as low as 1 in 10,000 cells.